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New analogs of vitamin D3. Calcitriol, the most active metabo- treatment can induce hypercalcemia, often precluding
lite of vitamin D, controls parathyroid gland growth and sup- the use of therapeutic doses. Hyperphosphatemia is also
presses the synthesis and secretion of parathyroid hormone a persistent problem among patients undergoing chronic(PTH). However, because of its potent effects on intestinal
hemodialysis and can be aggravated by therapeutic dosescalcium absorption and bone mobilization, calcitriol treatment
of 1,25(OH)2D3 [9, 10]. The use of large doses of calciumcan induce hypercalcemia, often precluding its use at therapeu-
tic doses. Hyperphosphatemia is also a persistent problem among carbonate or acetate to control phosphate absorption
patients undergoing chronic hemodialysis and can be aggravated only increases the risk of hypercalcemia resulting from
by therapeutic doses of calcitriol. Several pharmaceutical com- 1,25(OH)2D3 therapy [11–13]. Therefore an analog ofpanies were able to modify the side-chain of the 1,25(OH)2D3,
1,25(OH)2D3 that retains the therapeutic effects on PTHallowing some of these new analogs to retain the action on the
levels but has only minor impacts on calcium and phos-parathyroid glands while decreasing their hypercalcemic and
hyperphosphatemic effects. The structure-activity relationship phate metabolism would be an ideal tool for the treat-
for ligand-mediated transcriptional regulation has been studied ment of secondary hyperparathyroidism.
in detail. In some analogs the serum binding protein (DBP)
The biological actions of calcitriol are mediated by theplays a key role in determining the pharmacokinetics of the
nuclear vitamin D receptor (VDR). Upon binding 1,25vitamin D compound. The affinity to DBP for 22-oxacalcitriol
(OCT), an analog of calcitriol for the treatment of secondary (OH)2D3, the VDR undergoes a conformational change
hyperparathryoidism, is approximately 300–400 times lower and forms a complex with a retinoid X receptor (RXR).
than that of calcitriol and the analog is rapidly cleared from The VDR/RXR complex binds to specific sequences in
the circulation. The mechanisms for the selectivity of 19-nor-
target genes and may increase or decrease the rate of1,25(OH)2D2 (paricalcitol) (Zemplart) another analog of calcit-
gene transcription (Fig. 1). At present, there is evidenceriol, is clearly different from OCT. Although the mechanisms of
action is not completely known, it does appear that paricalcitol for only a single form of the VDR. Thus, the same VDR
down-regulates the VDR in the intestine. It is likely that the mediates both the calcemic actions and the nonclassical,
unique biological profiles of vitamin D analogs in vivo are due potentially therapeutic actions of calcitriol.to multiple mechanisms. Understanding the molecular basis of
The novel aspect of these analogs is their differentialthe analog selectivity will not only provide an explanation
actions, compared to 1,25(OH)2D3 in vivo. In fact, as thesefor their unique actions but allow intelligent design of more
effective analogs in the future. analogs have a relatively high affinity for the vitamin D
receptor, it is not unexpected that they are able to mimic
many of the actions of 1,25(OH)2D3 in vivo. The unique
The vitamin D hormone calcitriol (1,25(OH)2D3), the feature of the therapeutically useful analogs is the ability
most active metabolite of vitamin D, controls parathy- to efficiently support some but not all 1,25(OH)2D3 asso-
roid gland growth and suppresses the synthesis and secre- ciate activities. Most commonly, the analogs display de-
tion of parathyroid hormone (PTH) [1–5]. Because of its creased potency in enhancing intestinal absorption or
effects in PTH suppression, 1,25(OH)2D3 has been success- bone mobilization of calcium and phosphorus. In some
fully used in the treatment of secondary hyperparathy- cases, the analogs have a relatively high calcemic effect,
roidism which almost always accompanies chronic renal but tend to produce even higher activities in other spe-
failure [6–8]. The efficacy of intravenously administered cific cells or tissues. The selectivity is not always cell or
1,25(OH)2D3 in suppressing PTH levels in patient with tissue specific, but can be gene or process specific within
secondary hyperparathyroidism is well established. How- the same tissue.
ever, because of its potent effects on intestinal calcium The structure-activity relationship for ligand-mediated
absorption and bone calcium mobilization, 1,25(OH)2D3 transcriptional regulation has been studied in detail. The
A-ring structure is most crucial, especially the hydroxyl
groups, for binding to the VDR. Modification of the d-ringKey words: calcitriol, hypercalcimia, hyperphosphatemia, paricalcitol,
parathyroid hormone. or side chain does not greatly affect VDR binding, but
can influence biological potency by altering the pharma- 1999 by the International Society of Nephrology
S-46
Slatopolsky et al: New analogs of vitamin D3 S-47
cokinetics or catabolism. Analogs can also produce dis-
tinct conformational changes in the VDR that may pro-
duce gene-specific actions. A combination of structural
modifications can produce analogs with diverse biologi-
cal profiles.
MECHANISMS FOR ANALOG SELECTIVITY
In the past 10 years several laboratories have studied
the potential mechanisms involved in the selectivity of
vitamin D analogs [14]. The apparent tissue specificity
for the action of analogs can be attributed to several
potential mechanisms including 1) altered DBP affinity;
2) association with other serum carriers including lipo-
proteins; 3) altered cellular uptake; 4) accumulation of
active metabolites within the cell; 5) different rates of
catabolic inactivation; 6) differential activation of the non-
genomic pathway via a distinct membrane-bound receptor
(mVDR); 7) altered binding to the nuclear VDR leading
to changes (increases or decreases) in 8) VDR-RXR het-
erodimerization, 9) DNA binding of the VDR-RXR com-
plex, and 10) formation of the preinitiation complex [14]
(Fig. 2). Thus, differences in intracellular metabolism,
pharmacokinetics, nongenomic activities, and interac-
tions with the VDR may provide potential explanations
for the in vivo selectivity of any analog. Likely, more
than one of these mechanisms contribute to the unique
in vivo activity profile of each analog.
The serum vitamin D binding protein (DBP) plays
a key role in determining the pharmacokinetics of the
Fig. 1. Transcriptional control of gene expression by 1,25(OH)2D3. Thevitamin D compound. This protein binds all the natural
diagram shows the key steps involved in transcriptional regulation ofvitamin D metabolites and thereby greatly enhances the
1,25(OH)2D3: (1) Ligand binding to the vitamin D receptor (VDR); (2)circulating half-life, but at the same time it reduces their heterodimerization of VDR with retinoid X receptor (RXR); (3) bind-
ing of the VDR/RXR complex to the vitamin D response element; anduptake by the target tissue. Many of the side-chain–
(4) recruitment of components of the RNA polymerase II (Pol II)modified analogs have lower DBP affinity than 1,25
complex, including direct interactions with captivators (CoA) and tran-
(OH)2D3 which increases their clearance rate but allows scriptional factor IIB (B). (Reproduced with permission from [20]).
them to be more accessible to the target cells. The affinity
of 22-oxacalcitriol (OCT), one such analog, is approxi-
mately 300–400 times lower than that of 1,25(OH)2D3
and the analog is rapidly cleared from the circulation not known, but it does appear that paricalcitol down
[15–17]. At the same time, the tissue uptake of OCT is regulates the VDR in the intestine [19].
greater, but more transient, than that of 1,25(OH)2D3
[17, 18]. The short residence time of OCT in the intestine
SELECTIVE VITAMIN D ANALOGS FORand bone produces only transient increases in calcium
SECONDARY HYPERPARATHYROIDISMabsorption and bone mobilization [18]. However, the
The development of analogs for the treatment of sec-same pulse of OCT in the parathyroid glands elicits a
ondary hyperparathyroidism involves a series of evalua-prolonged suppression of PTH, probably due to the
tions. The first criterion was that the analog retainedlonger half-life of this response.
reasonably high affinity for the vitamin D receptor. AsThe mechanisms for the selectivity of 19-nor 1,25
we described above this will require the presence of an(OH)2D2 (paricalcitol) (Zemplart), another analog of
hydroxyl group at the 1 alpha position. The second crite-calcitriol, are clearly different from OCT. The DBP affin-
rion was that the analog had substantially less calcemicity of paricalcitol is nearly the same as that of 1,25(OH)2D3;
activity than 1,25(OH)2D3. Despite high VDR affinitiestherefore its clearance rate and time course of tissue
many analogs have greatly reduced abilities to raise serumlocalization are similar to those of 1,25(OH)2D3. The
mechanisms responsible for the action of paricalcitol are calcium. For example, the diminished calcemic action
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Fig. 2. Potential sites of differential action of
1,25(OH)2D3 and analogs. The possible stems
in the vitamin D activation pathways at which
differences in vitamin D analog action could
lead to selective activities in vivo are shown.
The steps diagramed include: (1) DBP affinity
(2) interaction with other serum proteins in-
cluding lipoproteins (3) cellular uptake (4)
conversion to active metabolism (5) catabolic
inactivation (6) activation of the nongenomic
pathway through a putative membrane vita-
min D receptor (mVDR) (7) interaction with
the nuclear vitamin D receptor (VDR) (8)
formation of the VDR-RXR complex (9) bind-
ing of the activated complex to DNA and (10)
formation of the preinitiation complex with
RNA polymerase II. (Reproduced with per-
mission from [14]).
Fig. 3. Chemical structure of calcitriol and several vitamin D analogs. (Reproduced with permission from [20]).
of 19-nor 1,25(OH)2D2 cannot really be attributed to cation. 1,25(OH)2D3 inhibits cell proliferation and pro-
motes cell differentiation. However, its use in conditionsdecreased binding to the VDR [20].
The third criterion was the ability to suppress PTH like psoriasis is limited by its calcemic activity. Calcipo-
triol on the other hand, was found to induce terminalsecretion not only in vitro but also in vivo, since some
of these analogs that are very effective in vitro are rapidly differentiation of cultured keratinocytes as potently as
1,25(OH)2D3 but it was more than 200 times less potentmetabolized in vivo and are unable to suppress second-
ary hyperparathyroidism. Currently there is substantial in raising serum and urinary calcium in normal rats when
given orally or intraperitoneally [22]. A series of analogsexperimental and clinical evidence with 2 analogs, 22-
oxacalcitriol (OCT) and 19-nor 1,25(OH)2D2 (paricalci- has been tested experimentally in the clinical arena for
the suppression of secondary hyperparathyroidism. One oftol, Zemplart). In addition there is clinical information
in regard to 1a-(OH)D2 [21]. these compounds, 22-oxacalcitriol (OCT), is made in Ja-
pan by Chugai Laboratories. It differs from 1,25(OH)2D3Figure 3 depicts the structure of 1,25(OH)2D3 and sev-
eral vitamin D analogs with important therapeutic appli- solely by the substitution of an oxygen atom for the
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methylene group at carbon 22 (Fig. 3). OCT can inhibit
pre pro PTH mRNA levels in vivo as effectively as
1,25(OH)2D3 [23]. In contrast OCT is less calcemic than
1,25(OH)2D3 in normal mice [24] and rats [23].
Furthermore, unpublished studies presented by Aki-
sawa et al in the renal osteodystrophy satellite sympo-
sium of the International Society of Nephrology Meeting
in Iguazu Falls, Australia (May 7–10, 1999), clearly dem-
onstrated the capability of this drug to suppress second-
ary hyperparathyroidism in patients with advanced renal
failure with minor changes in serum calcium. Thus, al-
though more studies are necessary to completely assess
the effectiveness of the drug, this analog apparently has
a significant therapeutic advantage over 1,25(OH)2D3 in
the control of secondary hyperparathyroidism without
inducing severe hypercalcemia and hyperphosphatemia
as observed with the administration of 1,25(OH)2D3.
Results obtained during a small clinical trial with
1a-hydroxyvitamin D2 have recently been published [21]. Fig. 4. The effects of 19-nor-1,25(OH)2D2 on serum PTH in normal
and uremic rats. All three doses of 19-nor-1,25(OH)2D2 (8, 25, and 75In this study, patients with moderate or severe secondary
ng) produced a significant decrease in circulating PTH levels. However,hyperparathyroidism received the vitamin D analog at none increased ionized calcium levels. *, P , 0.01; †, P , 0.02. j,
a dose of 4 mg daily or three times per week following pretreatment values; h, posttreatment values. (Reproduced with per-
mission from [25]).dialysis. During the study the mean drop in serum PTH
levels was slightly more than 50%. Serum calcium levels
rose slightly from 8.8 6 0.18 to 9.5 6 0.21 mg/dL (P ,
0.01). 1a-hydroxyvitamin D2 (Hectoral) has recently the course of the seven week study. Serum PTH levels
been approved for oral treatment of secondary hyper- dropped an average of approximately 60% (Fig. 5) with
parathyroidism. only a slight increase in serum calcium from 9.24 6
We have done extensive work with 19-nor-1,25(OH)2D2 0.12–9.56 6 0.15 dl (Fig. 6). There were only seven sig-
[25]. This analog has the carbon-28 and the double bond nificant episodes of hypercalcemia out of 414 determina-
at the carbon-22 that are characteristics of the vitamin D2 tions. However, in these patients the PTH concentrations
compounds, but it lacks the carbon-19 and the exocyclic had decreased to very low levels, ,100 pg/ml. Thus,
double bond found in all natural vitamin D metabolites the hypercalcemia likely was induced by an excessive
(Fig. 3). We demonstrated that 19-nor-1,25(OH)2D2 sup- administration of this analog. Since physicians have
presses parathyroid hormone secretion in primary cultures learned that a PTH of 300 pg/ml usually is accompanied
of bovine parathyroid cells as potently as 1,25(OH)2D3. by normal bone histology, in this study the physicians
In addition, this compound can suppress pre pro PTH should have decreased the dose of 19-nor-1,25(OH)2D2
messenger RNA and PTH secretion without inducing when they observed such a major decrease in the levels
hypercalcemia or hyperphosphatemia (Fig. 4). Daily ad- of serum PTH. Presumably, this would have further re-
ministration of 19-nor 1,25(OH)2D2 to parathyroidecto- duced incidence of hypercalcemia.
mized rats fed either a calcium- or a phosphorus-deficient
diet for 9 days produced smaller increases in plasma cal-
CONCLUSIONcium and phosphorus than 1,25(OH)2D3. Dose–response
studies demonstrated that 19-nor-1,25(OH)2D2 is approxi- The predominant form of selectivity observed is that
the analog has a much lower calcemic and phosphatemicmately 10 times less active than 1,25(OH)2D3 in mobiliz-
ing calcium and phosphorus from bone [26]. Moreover, activity than expected on the basis of nuclear VDR affin-
ity and apparent high activity in vitro. Many of thesein contrast to 1,25(OH)2D3 that up regulates the VDR
in the intestine, 19-nor 1,25(OH)2D2 has the opposite analogs have been found to have low affinity for DBP
and are therefore more rapidly cleared from the circula-effect [19].
The efficacy of 19-nor-1,25(OH)2D2 in renal failure tion, but at the same time they may be more accessible
to target tissues. Pharmacokinetic changes may explainpatients was demonstrated in a recent study [27] in 78
patients; placebo was given to approximately one-third most of the differences in activity found with 22-oxacalci-
triol compared to 1,25(OH)2D3. The rate of intracellularof the patients, and 19-nor-1,25(OH)2D2 was adminis-
tered to two-thirds of the patients. The dose was initially catabolism can vary with cell type and may produce
tissue-specific effects of the analogs. Vitamin D analogs0.04 mg and rose to an average of 0.12 mg/kg during
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Fig. 5. Changes in the levels of intact PTH
expressed as a percentage of change from
baseline values during the study period in pla-
cebo-treated (s) and paricalcitol-treated (d)
groups. The bars depict the doses of paricalci-
tol that increase according to protocol. (Re-
produced with permission from [27]).
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